Modulation of olfactory area for effective transportation of actives in CNS disorders

Author(s):  
Harshvardhan Jain ◽  
Bala Prabhakar ◽  
Pravin Shende
Keyword(s):  
2008 ◽  
Author(s):  
Missy Coblentz ◽  
Kim Bond ◽  
Pennie S. Seibert ◽  
Carin M. Patterson ◽  
Caitlin C. Otto ◽  
...  
Keyword(s):  

2014 ◽  
Vol 21 (23) ◽  
pp. 2599-2609 ◽  
Author(s):  
Chung Chin ◽  
Diego Chiba ◽  
Marcella Machado ◽  
Ednir Vizioli ◽  
Jean Santos
Keyword(s):  

2020 ◽  
Vol 21 ◽  
Author(s):  
Aashish Sharma ◽  
Romila Manchanda ◽  
Faheem Hyder Pottoo ◽  
Ghulam Md. Ashraf

: Impressive research steps have been taken for the treatment of neurological disorders in the last few decades. Still effective treatments of brain related disorders are very less due to problems associated with crossing the blood brain barrier (BBB), non-specific therapies, and delay in functional recovery of central nervous system (CNS) after treatment. Striving for novel treatment options for neurological disorders, nanotechnology-derived materials, and devices have gained the ground due to inherent features of derivatization/encapsulation with drugs as per the neurological ailments and pharmacological targets. Facile developments/syntheses of the nanomaterials-drug conjugates have also been the driving force for researchers to get into this field. Moreover, the tunable size and hydro/lipophilicity of these nanomaterials are the added advantages that make these materials more acceptable for CNS disorders. These nano-neurotherapeutics (NNTs) systems provide the platform for diagnosis, theranostics, treatments, restoration of CNS disorders, and encourage the translation of NNTs from “bench to bedside”. Still, these techniques are in primary stages of medical development. This review describes the latest advancements and future scenarios of developmental and clinical aspects of polymeric NNTs.


2015 ◽  
Vol 15 (8) ◽  
pp. 630-647 ◽  
Author(s):  
F.J.B. Junior ◽  
L. Scotti ◽  
H. Ishiki ◽  
S.P.S. Botelho ◽  
M.S. Silva ◽  
...  
Keyword(s):  

2004 ◽  
Vol 3 (3) ◽  
pp. 181-194 ◽  
Author(s):  
Michael O'Neill ◽  
David Bleakman ◽  
Dennis Zimmerman ◽  
Eric Nisenbaum

2020 ◽  
Vol 20 (13) ◽  
pp. 1142-1153 ◽  
Author(s):  
Sreyashi Chandra ◽  
Md. Tanjim Alam ◽  
Jhilik Dey ◽  
Baby C. Pulikkaparambil Sasidharan ◽  
Upasana Ray ◽  
...  

Background: The central nervous system (CNS) known to regulate the physiological conditions of human body, also itself gets dynamically regulated by both the physiological as well as pathological conditions of the body. These conditions get changed quite often, and often involve changes introduced into the gut microbiota which, as studies are revealing, directly modulate the CNS via a crosstalk. This cross-talk between the gut microbiota and CNS, i.e., the gut-brain axis (GBA), plays a major role in the pathogenesis of many neurodegenerative disorders such as Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Huntington’s disease (HD). Objective: We aim to discuss how gut microbiota, through GBA, regulate neurodegenerative disorders such as PD, AD, ALS, MS and HD. Methods: In this review, we have discussed the present understanding of the role played by the gut microbiota in neurodegenerative disorders and emphasized the probable therapeutic approaches being explored to treat them. Results: In the first part, we introduce the GBA and its relevance, followed by the changes occurring in the GBA during neurodegenerative disorders and then further discuss its role in the pathogenesis of these diseases. Finally, we discuss its applications in possible therapeutics of these diseases and the current research improvements being made to better investigate this interaction. Conclusion: We concluded that alterations in the intestinal microbiota modulate various activities that could potentially lead to CNS disorders through interactions via the GBA.


2013 ◽  
Vol 12 (7) ◽  
pp. 1066-1077 ◽  
Author(s):  
Yan Zeng ◽  
Xiaonan Wang ◽  
Qiang Wang ◽  
Shumin Liu ◽  
Xiamin Hu ◽  
...  

2020 ◽  
Vol 18 (9) ◽  
pp. 687-694 ◽  
Author(s):  
Sydney Corey ◽  
Lauren Kvederis ◽  
Chase Kingsbury ◽  
Brooke Bonsack ◽  
Paul R. Sanberg ◽  
...  

: Here, we summarized recent advances in laboratory and clinical research on gut microbiome. The goal is to highlight recent discoveries on the biology and behavioral manifestations of gut microbiomes under normal and pathologic conditions. With this new scientific knowledge, we wish to cultivate cross-fertilization of science across multi-disciplines in the hopes of exploiting the gut microbiome as a key component of human development and its dysbiosis may signal pathological alterations that can be therapeutically targeted for regenerative medicine. In the end, we identify innovative research avenues that will merit from collaborations across biomedical disciplines that may facilitate the development of gut microbiome-based biomarkers and therapeutics. Gut microbiome stands as a core research area that transcends pediatric and nursing care, cancer biology, neurodegenerative disorders, cardiac function and diseases, among many other basic science and clinical arenas.


Sign in / Sign up

Export Citation Format

Share Document